Sense Biodetection has raised $15.8m in a series A round co-led by Cambridge Innovation Capital and Earlybird to produce a diagnostic test for infectious diseases.
Sense Biodetection, a UK-based molecular diagnostic tests developer, raised £12.3m ($15.8m) in a series A round on Tuesday co-led by university-affiliated patient capital fund Cambridge Innovation Capital (CIC) and VC firm Earlybird.
Sense Biodetection is creating a range of instrument-free, point-of-care molecular diagnostic tests that it will initially use to detect infectious diseases such as influenza. Due to their nature of being single us and not requiring instruments, Sense’s tests could be deployed in any setting.
The series…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
